menu
    • menu
    [{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Neurelis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aculys Pharma \/ Neurelis","highestDevelopmentStatusID":"15","companyTruncated":"Aculys Pharma \/ Neurelis"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aculys Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aculys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aculys Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2025","type":"Acquisition","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aculys Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Aculys Pharma \/ Viatris"}]

    Find Clinical Drug Pipeline Developments & Deals by Aculys Pharma

    Menu

    Aculys Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Viatris Acquires Aculys, Gains Rights to Pitolisant and Spydia® in Japan and Asia-Pacific

                            Details : Under the acquisition of Diazepam, a controlled substance targeting GABA-A receptor, the deal aims to advance treatment for excessive daytime sleepiness (EDS).

                            Product Name : Spydia

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 15, 2025

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aculys Pharma Delivers Positive Phase 3 Clinical Study Interim Analysis Result of a Diazepam Nasal Spray: an A...

                            Details : NRL-1 (diazepam) nasal spray act as inhibitory effects of gamma-aminobutyric acid (GABA), which is investigated for the treatment of epileptic seizures.

                            Product Name : Valtoco

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aculys Pharma Initiates Phase 3 Trial of Pitolisant Treating Patients with Excessive Daytime Sleepiness Associ...

                            Details : BF2.649 (pitolisant hydrochloride) is an antagonist/inverse agonist that binds to the histamine H3 receptor, an autoreceptor located in the presynaptic region of the histamine-containing neurons in the human brain that plays a critical role in regulating...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2023

                            Lead Product(s) : Pitolisant Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Aculys Pharma

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Neurelis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aculys Pharma Signed an Exclusive Licensing Agreement with Neurelis, Inc. for The Development and Commercializ...

                            Details : Aculys Pharma signed licensing agreement with Neurelis, for the development and commercialization of VALTOCO (diazepam nasal spray), approved by the FDA in the United States for the acute treatment of seizure clusters in patients with epilepsy six years ...

                            Product Name : Valtoco

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Neurelis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth